SEC Form 4 · accession 0001225208-18-012185

Edwards Lifesciences Corp · EW

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Michael A Mussallem

Officer — Chairman & CEO · Director

Period of report

Jul 31, 2018

Accepted (ET)

Aug 2, 2018 · 4:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001099800

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 25, 2018	G	47,305	$0.00	D	43,126	D
Common Stock	Jul 31, 2018	M	32,900	$42.725	A	76,026	D
Common Stock^F2	Jul 31, 2018	S	400	$143.0275	D	75,626	D
Common Stock^F3	Jul 31, 2018	S	2,915	$140.3053	D	72,711	D
Common Stock^F4	Jul 31, 2018	S	12,807	$141.6073	D	59,904	D
Common Stock^F5	Jul 31, 2018	S	16,778	$142.3013	D	43,126	D
Common Stock	Jul 25, 2018	G	47,305	$0.00	A	745,400	I	By Living Trust
Common Stock	holding	—	—		—	123,931	I	401(k)

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Acquire)	$42.725	Jul 31, 2018	M	32,900	D	Jun 9, 2012	May 8, 2019	Common Stock	32,900	254,000	D

Explanation of responses

F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018.
F2This transaction was executed in multiple trades at prices ranging from $142.95 to $143.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $139.91 to $140.86. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4This transaction was executed in multiple trades at prices ranging from $140.92 to $141.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F5This transaction was executed in multiple trades at prices ranging from $141.92 to $142.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.